Fulcrum Therapeutics, Inc. Common Stock
FULC Real Time Price USDRecent trades of FULC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FULC's directors and management
Government lobbying spending instances
-
$60,000 Oct 21, 2024 Issue: Pharmacy
-
$60,000 Jul 19, 2024 Issue: Pharmacy
-
$30,000 Apr 19, 2024 Issue: None
-
$30,000 Jan 22, 2024 Issue: None
-
$30,000 Oct 20, 2023 Issue: Health Issues
-
$30,000 Jul 19, 2023 Issue: Health Issues
-
$30,000 Apr 20, 2023 Issue: Health Issues
-
$30,000 Jan 19, 2023 Issue: Health Issues
-
$20,000 Oct 18, 2022 Issue: None
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Macrocyclic azolopyridine derivatives as eed and prc2 modulators Oct. 08, 2024
-
Patent Title: Macrocyclic azolopyridine derivatives as eed and prc2 modulators Feb. 28, 2023
-
Patent Title: Use of p38 inhibitors to reduce expression of dux4 Oct. 25, 2022
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Apr. 05, 2022
-
Patent Title: Macrocyclic azolopyridine derivatives as eed and prc2 modulators Apr. 13, 2021
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Jan. 21, 2020
-
Patent Title: P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd Jul. 09, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of FULC in WallStreetBets Daily Discussion
Recent insights relating to FULC
Recent picks made for FULC stock on CNBC
ETFs with the largest estimated holdings in FULC
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FULC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.